The Lancet Commission on global mental health and sustainable development

The Lancet, Journal Year: 2018, Volume and Issue: 392(10157), P. 1553 - 1598

Published: Oct. 1, 2018

Language: Английский

---

Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology

Journal of Psychopharmacology, Journal Year: 2016, Volume and Issue: 30(6), P. 495 - 553

Published: March 15, 2016

The British Association for Psychopharmacology guidelines specify the scope and target of treatment bipolar disorder. second version, like first, is based explicitly on available evidence presented, previous Clinical Practice guidelines, as recommendations to aid clinical decision making practitioners: they may also serve a source information patients carers. are presented together with more detailed but selective qualitative review evidence. A consensus meeting, involving experts in disorder its treatment, reviewed key areas considered strength implications. were drawn up after extensive feedback from participants interested parties. supporting was rated. cover diagnosis disorder, management, strategies use medicines episodes, relapse prevention stopping treatment.

Language: Английский

---

The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder

Neuroscience & Biobehavioral Reviews, Journal Year: 2021, Volume and Issue: 128, P. 789 - 818

Published: Feb. 5, 2021

Misconceptions about ADHD stigmatize affected people, reduce credibility of providers, and prevent/delay treatment. To challenge misconceptions, we curated findings with strong evidence base.

Language: Английский

---

Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines

Journal of Psychopharmacology, Journal Year: 2015, Volume and Issue: 29(5), P. 459 - 525

Published: May 1, 2015

A revision of the 2008 British Association for Psychopharmacology evidence-based guidelines treating depressive disorders with antidepressants was undertaken in order to incorporate new evidence and update recommendations where appropriate. consensus meeting involving experts their management held September 2012. Key areas depression were reviewed strength clinical implications considered. The then revised after extensive feedback from participants interested parties. literature review is provided which identifies quality upon are made. These cover nature detection disorders, acute treatment antidepressant drugs, choice drug versus alternative treatment, practical issues prescribing management, next-step relapse prevention, stopping treatment. Significant changes since last published include availability options, improved supporting certain augmentation strategies (drug non-drug), potential long-term side effects, updated guidance elderly adolescent populations optimal prescribing. Suggestions future research priorities also

Language: Английский

---

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Update 2013 on the acute and continuation treatment of unipolar depressive disorders

The World Journal of Biological Psychiatry, Journal Year: 2013, Volume and Issue: 14(5), P. 334 - 385

Published: July 1, 2013

Objectives. This 2013 update of the practice guidelines for biological treatment unipolar depressive disorders was developed by an international Task Force World Federation Societies Biological Psychiatry (WFSBP). The goal has been to systematically review all available evidence pertaining disorders, and produce a series recommendations that are clinically scientifically meaningful based on evidence. intended use physicians seeing treating patients with these conditions. Methods. conducted systematic literature search appraisal. All were approved Guidelines Force. Results. first part (Part 1) covers disease definition, classification, epidemiology, course as well management acute continuation phase treatment. It is primarily concerned (including antidepressants, other psychopharmacological medications, electroconvulsive therapy, light adjunctive novel therapeutic strategies) adults. Conclusions. To date, there variety evidence-based antidepressant options available. Nevertheless still substantial proportion not achieving full remission. In addition, somatic psychiatric comorbidities special circumstances need be more thoroughly investigated. Therefore, further high-quality informative randomized controlled trials urgently needed.

Language: Английский

---

Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology

Journal of Psychopharmacology, Journal Year: 2019, Volume and Issue: 34(1), P. 3 - 78

Published: Dec. 12, 2019

These updated guidelines from the British Association for Psychopharmacology replace original version published in 2011. They address scope and targets of pharmacological treatment schizophrenia. A consensus meeting was held 2017, involving experts schizophrenia its treatment. were asked to review key areas consider strength evidence on risk-benefit balance interventions clinical implications, with an emphasis meta-analyses, systematic reviews randomised controlled trials where available, plus updates current practice. The cover management across various stages illness, including first-episode, relapse prevention, illness that has proved refractory standard It is hoped practice recommendations presented will support decision making practitioners, serve as a source information patients carers, inform quality improvement.

Language: Английский

---

Antipsychotic medication in schizophrenia: a review

British Medical Bulletin, Journal Year: 2015, Volume and Issue: 114(1), P. 169 - 179

Published: May 8, 2015

Antipsychotic medications are mainstays in the treatment of schizophrenia and a range other psychotic disorders. Recent meta-analyses antipsychotic efficacy tolerability have been included this review, along with key papers on use illnesses. The heterogeneity terms individuals' response to current inability predict leads trial-and-error strategy choice. Clozapine is only effective medication for treatment-resistant schizophrenia. There significant number side effects associated use. With reduction frequency extrapyramidal second-generation antipsychotics, there has shift effect burden, an increase risk cardiometabolic dysfunction. exist small robust differences between (other than clozapine), each drug vary, being no first-line that suitable all patients. A focus different symptom domains may lead endophenotypic markers identified, e.g. negative symptoms cognitive deficits (as well as positive symptoms) can promote development novel therapeutics, which will rationally target cellular molecular targets, rather just dopamine 2 receptor. Future developments additional processes, including glutamatergic, cholinergic cannabinoid receptor targets utilize personalized medicine techniques, such pharmacogenetic variants biomarkers allowing tailored safer antipsychotics.

Language: Английский

---

The Personalized Advantage Index: Translating Research on Prediction into Individualized Treatment Recommendations. A Demonstration

PLoS ONE, Journal Year: 2014, Volume and Issue: 9(1), P. e83875 - e83875

Published: Jan. 8, 2014

Background Advances in personalized medicine require the identification of variables that predict differential response to treatments as well development and refinement methods transform predictive information into actionable recommendations. Objective To illustrate test a new method for integrating aid treatment selection, using data from randomized comparison. Method Data trial antidepressant medications (N = 104) versus cognitive behavioral therapy 50) Major Depressive Disorder were used produce predictions post-treatment scores on Hamilton Rating Scale Depression (HRSD) each two 154 patients. The patient's own not models yielded these predictions. Five pre-randomization predicted (marital status, employment life events, comorbid personality disorder, prior medication trials) included regression models, permitting calculation Personalized Advantage Index (PAI), HRSD units. Results For 60% sample clinically meaningful advantage (PAI≥3) was one treatments, relative other. When patients divided those randomly assigned their "Optimal" "Non-optimal" treatment, outcomes former group superior (d 0.58, 95% CI .17—1.01). Conclusions This approach implemented context equally effective effects that, if obtained prospectively, would rival routinely observed comparisons active control treatments.

Language: Английский

---

Pharmacotherapy for post-traumatic stress disorder: Systematic review and meta-analysis

The British Journal of Psychiatry, Journal Year: 2015, Volume and Issue: 206(2), P. 93 - 100

Published: Feb. 1, 2015

Background Pharmacological treatment is widely used for post-traumatic stress disorder (PTSD) despite questions over its efficacy. Aims To determine the efficacy of all types pharmacotherapy, as monotherapy, in reducing symptoms PTSD, and to assess acceptability. Method A systematic review meta-analysis randomised controlled trials was undertaken; 51 studies were included. Results Selective serotonin reuptake inhibitors found be statistically superior placebo reduction PTSD but effect size small (standardised mean difference −0.23, 95% CI −0.33 −0.12). For individual pharmacological agents compared with two or more trials, we significant evidence fluoxetine, paroxetine venlafaxine. Conclusions Some drugs have a positive impact on are acceptable. Fluoxetine, venlafaxine may considered potential treatments disorder. most there inadequate regarding pointing need research this area.

Language: Английский

---

Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies

BMJ, Journal Year: 2014, Volume and Issue: 348(mar19 5), P. g1888 - g1888

Published: March 19, 2014

Objective To systematically review published and unpublished efficacy studies of agomelatine in people with depression. Design Systematic meta-analysis. Data sources Literature search (Pubmed, Embase, Medline), Cochrane Central Register Controlled Trials, European Medicines Agency (EMA) regulatory file for agomelatine, manufacturers (Servier). Eligibility criteria Double blind randomised placebo comparator controlled trials depression standard rating scales. synthesis Studies were pooled by using a random effects model DerSimonian Laird weights comparisons antidepressant. The primary measure (change scale score) was summarised standardised mean difference (SMD; effect size) secondary outcome measures relative risks. All results presented 95% confidence intervals. Statistical heterogeneity explored visual inspection funnel plots the I² statistic. Moderators meta-regression. Results We identified 20 7460 participants meeting inclusion criteria (11 literature, four from file, five manufacturer). Almost all used 17 item Hamilton (score 0-50). Agomelatine significantly more effective than an size (SMD) 0.24 (95% interval 0.12 to 0.35) risk response 1.25 (1.11 1.4). Compared other antidepressants, showed equal (SMD 0.00, −0.09 0.10). Significant uncovered most analyses, though bias low. Published likely have that suggested advantages agomelatine. Conclusions is antidepressant similar antidepressants. generally had favourable studies.

Language: Английский

---